Rituximab treatment for lupus nephritis: A systematic review

被引：1
作者：
Yuan, Zijie [1 ]
Xie, Qifang [2 ]
Wu, Xiaochuan [3 ]
Tan, Boyu [4 ]
Zhang, Xianhua [1 ]
机构：
[1] Hunan Normal Univ, Affiliated Hosp 1, Pediat Med Ctr, Hunan Prov Peoples Hosp, Changsha, Peoples R China
[2] Changsha Cent Hosp, Dept Pediat, Changsha, Peoples R China
[3] Cent South Univ, Xiangya Hosp 2, Pediat Med Ctr, Changsha, Peoples R China
[4] Hunan Normal Univ, Affiliated Hosp 1, Div Pharm, Hunan Prov Peoples Hosp, Changsha, Peoples R China
来源：
CLINICAL AND INVESTIGATIVE MEDICINE | 2020年 / 43卷 / 02期
关键词：
MYCOPHENOLATE-MOFETIL; POOLED DATA; CYCLOPHOSPHAMIDE; EFFICACY; THERAPY; SAFETY; ERYTHEMATOSUS;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Purpose: We used the Cochrane systematic review to analyze the effectiveness and safety of rituximab for lupus nephritis. Methods: Systematic search was performed among Cochrane clinical controlled trials database, MEDLINE, MEDLINE-IN-Process and Other Non-Indexed Citations, EMBASE, EBSCO CINAHL, CNKI, VIP and Wanfang database from the establishment of the database to February 2016. The effectiveness and safety were evaluated in terms of the complete remission rate, total remission rate, urinary protein, Systemic Lupus Erythematosus Disease Activity Index changes and adverse events rate. Data were analyzed by the Review Manager Software version 5.3. Results: Five RCTs that met the inclusion criteria, including a total of 238 patients, were enrolled in our study. The results showed that the complete remission rate in rituximab group was a significantly higher than that of cyclophosphamide group. The difference between the two groups was statistically significant (OR=2.80, 95%CI(1.08,7.26), P=0.03). But there was no significant difference between the two groups in partial and total remission rate. The complete remission rate, partial remission rate and total remission rate in rituximab treatment group was similar compared with mycophenolate mofetil group and rituximab combined with cyclophosphamide group. The adverse reaction rate was also similar among the groups. Conclusion: The study systematically analyzed the effectiveness and safety of rituximab for lupus nephritis, which suggested that the complete remission rate of rituximab in the treatment of lupus nephritis was a significantly higher than that of cyclophosphamide group, while the effectiveness and safety was of no difference compared with cyclophosphamide and mycophenolate mofetil.
引用
收藏
页码：E47 / E54
页数：8
相关论文
共 27 条
[1]   Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study [J].
Boletis, John N. ;
Marinaki, Smaragde ;
Skalioti, Chryssanthe ;
Lionaki, Sofia S. ;
Iniotaki, Aliki ;
Sfikakis, Petros P. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2009, 24 (07) :2157-2160
[2]   Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus [J].
Catapano, Fausta ;
Chaudhry, Afzal N. ;
Jones, Rachel B. ;
Smith, Kenneth G. C. ;
Jayne, David W. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2010, 25 (11) :3586-3592
[3]   Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids [J].
Condon, Marie B. ;
Ashby, Damien ;
Pepper, Ruth J. ;
Cook, H. Terence ;
Levy, Jeremy B. ;
Griffith, Megan ;
Cairns, Tom D. ;
Lightstone, Liz .
ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (08) :1280-1286
[4]   Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis [J].
Davies, R. J. ;
Sangle, S. R. ;
Jordan, N. P. ;
Aslam, L. ;
Lewis, M. J. ;
Wedgwood, R. ;
D'Cruz, D. P. .
LUPUS, 2013, 22 (06) :574-582
[5]   Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts [J].
Diaz-Lagares, Candido ;
Croca, Sara ;
Sangle, Shirish ;
Vital, Edward M. ;
Catapano, Fausta ;
Martinez-Berriotxoa, Agustin ;
Garcia-Hernandez, Francisco ;
Callejas-Rubio, Jose-Luis ;
Rascon, Javier ;
D'Cruz, David ;
Jayne, David ;
Ruiz-Irastorza, Guillermo ;
Emery, Paul ;
Isenberg, David ;
Ramos-Casals, Manuel ;
Khamashta, Munther A. .
AUTOIMMUNITY REVIEWS, 2012, 11 (05) :357-364
[6]  
Fan Z, 2009, CHINESE REMEDIES CLI, V9, P675
[7]   Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis [J].
Gunnarsson, Iva ;
Sundelin, Birgitta ;
Jonsdottir, Thorunn ;
Jacobson, Stefan H. ;
Henriksson, Elisabet Welin ;
van Vollenhoven, Ronald F. .
ARTHRITIS AND RHEUMATISM, 2007, 56 (04) :1263-1272
[8]   Long-term follow-up in lupus nephritis patients treated with rituximab-clinical and histopathological response [J].
Jonsdottir, Thorunn ;
Zickert, Agneta ;
Sundelin, Birgitta ;
Henriksson, Elisabet W. ;
van Vollenhoven, Ronald F. ;
Gunnarsson, Iva .
RHEUMATOLOGY, 2013, 52 (05) :847-855
[9]   Clinical improvements in proliferative vs membranous lupus nephritis following B-cell depletion: pooled data from two cohorts [J].
Jonsdottir, Thorunn ;
Gunnarsson, Iva ;
Mourao, Ana Filipa ;
Lu, Tim Y. ;
van Vollenhoven, Ronald F. ;
Isenberg, David .
RHEUMATOLOGY, 2010, 49 (08) :1502-1504
[10]   Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? [J].
Li, Edmund K. ;
Tam, Lai-Shan ;
Zhu, Tracy Y. ;
Li, Martin ;
Kwok, Catherine L. ;
Li, Tena K. ;
Leung, Ying Ying ;
Wong, Kong Chiu ;
Szeto, Cheuk Chun .
RHEUMATOLOGY, 2009, 48 (08) :892-898
123